Skip to main content
. 2017 Feb 14;356:j504. doi: 10.1136/bmj.j504

Table 3.

CIN detection rates per 100 000 screening samples and 72 month cumulative cervical cancer incidence after 100 000 normal screening samples for conventional cytology, and difference in those measures for SurePath and ThinPrep compared with conventional cytology

Conventional cytology SurePath v conventional cytology ThinPrep v conventional cytology
No of CIN diagnoses per 100 000 screening samples
CIN I 216.1 30.1 (18.1 to 42.8) −3.5 (−14.3 to 7.9)
CIN II 220.0 31.2 (19.0 to 44.1) 9.4 (−2.1 to 21.5)
CIN III 495.0 30.3 (12.0 to 49.3) −12.2 (−29.6 to 5.9)
Total CIN 931.0 94.4 (68.9 to 120.6) −6.8 (−30.6 to 17.6)
No of cervical cancer diagnoses after 100 000 normal screening samples *
Total cancers 58.5 (54.6 to 62.7) −11.9 (−15.6 to −4.2) +8.5 (−0.7 to 18.8)

Numbers were corrected for confounding factors. 95% confidence intervals are given in parentheses.

CIN=cervical intraepithelial neoplasia.

*Differences in distribution of follow-up were taken into account, and laboratories were included as random effects in model.